Nesina
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Nesina (alogliptin; Takeda) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class. DPP-IV is an enzyme responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1 (GLP-1), which is released postprandially from the gut. Inhibition of DPP-IV augments the amount of active GLP-1, which in turn triggers increased insulin secretion from the pancreas in a glucose-dependent manner and suppresses the release of glucagon, resulting in lowered blood glucose levels. Generic alogliptin was approved by the US Food and Drug Administration in April 2016.
The franchise products Oseni ([alogliptin + pioglitazone]; Takeda) and Kazano ([alogliptin + metformin]; Takeda) address the fact that Nesina is generally used as a second- or third-line treatment option.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Nesina : Diabetes type 2
LIST OF FIGURES
10 Figure 1: Nesina brand franchise for type 2 diabetes – SWOT analysis
11 Figure 2: Datamonitor Healthcare drug assessment of Nesina
12 Figure 3: Datamonitor Healthcare drug assessment scorecard for Nesina compared to Januvia
14 Figure 4: Nesina sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
16 Figure 5: Oseni sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
4 Table 1: Nesina franchise products
5 Table 2: Nesina drug profile
5 Table 3: Oseni drug profile
6 Table 4: Kazano drug profile
7 Table 5: Overview of pivotal trial data for Nesina franchise in diabetes
15 Table 6: Nesina sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
17 Table 7: Oseni sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Lusefi 
Sign up to the